TY  - GEN
AU  - García-Romero, N
AU  - Palacín-Aliana, I
AU  - Madurga, R
AU  - Carrión-Navarro, J
AU  - Esteban-Rubio, Susana
AU  - Jiménez, B
AU  - Collazo, A
AU  - Pérez-Rodríguez, F
AU  - Ortiz de Mendivil, A
AU  - Fernández-Carballal, C
AU  - García-Duque, S
AU  - Diamantopoulos-Fernández, J
AU  - Belda-Iniesta, Cristobal
AU  - Prat-Acín, R
AU  - Calvo, E
AU  - Ayuso-Sacido, Angel
AU  - Sánchez-Gómez, Pilar
PY  - 2020
DO  - 10.1186/s12916-020-01610-0
SN  - 1741-7015
UR  - http://hdl.handle.net/20.500.12105/10986
AB  - Glioblastoma (GBM) is one of the most aggressive and vascularized brain tumors in adults, with a median survival of 20.9 months. In newly diagnosed and recurrent GBM, bevacizumab demonstrated an increase in progression-free survival, but not in...
LA  - eng
PB  - BioMed Central (BMC)
KW  - Angiogenesis
KW  - Bevacizumab
KW  - Glioblastoma
KW  - Neovasculogenesis
KW  - VEGFA
TI  - Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma.
TY  - research article
ER  -